Clinical Trial Update: S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation [Phase 3]

View source ↗

Summary

Phase 3 trial update for S.I.F.A. II assessing prevention of thromboembolic events in nonrheumatic atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Snippet

Sponsor: Pfizer | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED